Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome

NCT06834594

Status	RECRUITING
Phase	Phase 4
Sponsor	Children's Mercy Hospital Kansas City
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of Turner Syndrome and Primary Ovarian Insufficiency.
- Prescribed adult dosing* of transdermal or oral estradiol for estrogen replacement therapy.
- *Adult dosing of will be defined per published clinical practice guidelines from the 2023 International Turner Syndrome Meeting (i.e. 50-200µg/day of transdermal estradiol, or (i.e. 50-200µg/day of transdermal estradiol or 2-4mg/day oral estradiol).
- Have achieved menarche.

Exclusion (4)

- Disclosure of sexual activity and desire for contraception.
- Having a levonorgestrel-releasing intrauterine device or etonogestrel arm implant in place.
- Having received depot medroxyprogesterone within one year prior to study recruitment.
- Non-English or non-Spanish speaking.

Locations (1 total)

Children's Mercy Hospital, Kansas City, Missouri, United States